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Abstract
GPR55 was recently identified as a putative receptor for certain cannabinoids, and lysophosphatidylinositol (LPI). Recently,
the role of cannabinoids as GPR55 agonists has been disputed by a number of reports, in part, because studies investigating
GPR55 often utilized overexpression systems, such as the GPR55-overexpressing HEK293 cells, which make it difficult to
deduce the physiological role of endogenous GPR55. In the present study, we found that PC12 cells, a neural model cell line,
express endogenous GPR55, and by using these cells, we were able to examine the role of endogenous GPR55. Although
GPR55 mRNA and protein were expressed in PC12 cells, neither CB1 nor CB2 mRNA was expressed in these cells. GPR55 was
predominantly localized on the plasma membrane in undifferentiated PC12 cells. However, GPR55 was also localized in the
growth cones or the ruffled border in differentiated PC12 cells, suggesting a potential role for GPR55 in the regulation of
neurite elongation. LPI increased intracellular Ca
2+ concentration and RhoA activity, and induced ERK1/2 phosphorylation,
whereas endogenous and synthetic cannabinoids did not, thereby suggesting that cannabinoids are not GPR55 agonists.
LPI also caused neurite retraction in a time-dependent manner accompanied by the loss of neurofilament light chain and
redistribution of actin in PC12 cells differentiated by NGF. This LPI-induced neurite retraction was found to be Gq-
independent and G13-dependent. Furthermore, inactivation of RhoA function via C3 toxin and GPR55 siRNA knockdown
prevented LPI-induced neurite retraction. These results suggest that LPI, and not cannabinoids, causes neurite retraction in
differentiated PC12 cells via a GPR55, G13 and RhoA signaling pathway.
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Introduction
Cannabinoids, which include the bioactive constituents of the
marijuana plant Cannabis sativa and its synthetic or endogenous
counterparts, modulate a range of central nervous system
functions, and affect peripheral sites, such as immune function
and the cardiovascular system [1,2]. Several endogenous canna-
binoid ligands have been isolated, including anandamide [3] and
2-arachidonoyl-glycerol (2-AG) [4,5]. To date, two classical
cannabinoid receptors have been identified, specifically cannabi-
noid receptor type 1 (CB1) [6] and cannabinoid receptor type 2
(CB2) [7]. CB1 is predominantly expressed within the central
nervous system [8], whereas CB2 is mainly expressed within the
immune system [7]. Both cannabinoid receptors are coupled with
Pertussis toxin-sensitive Gi/o-proteins [1], and activation of CB1
and CB2 receptors reduces a forskolin-induced cyclic AMP
accumulation [9].
In addition to CB1 and CB2 receptors, an orphan G-protein-
coupled receptor, GPR55, was recently identified as a novel
putative cannabinoid receptor [10]. However, GPR55 shares a low
homology with the amino acid sequence of CB1 (13.5%) or CB2
(14.4%). GPR55 was first reported as an orphan receptor expressed
extensively in the human brain [11], suggesting that GPR55
regulates neuronal function. Cannabinoids, including 9-tetrahy-
drocannabinol (THC), CP55940, anandamide, 2-AG, O1602, and
abnormal cannabidiol, are GPR55 agonists, whereas cannabidiol is
an antagonist,as determinedbyGTPcS bindingassay [12]. O1602-
stimulated GTPcS binding is blocked by Ga13 carboxy-terminus
and Ga13 antibody, suggesting that GPR55 interacts with G13.
THC increases intracellular Ca
2+ concentrations ([Ca
2+]i)v i a
GPR55, Gq and RhoA, however, some cannabinoids, such as 2-
AG and CP55940, have no effect on [Ca
2+]i [13]. Conversely,
anandamide and 2-AG have no effect on GPR55 activation, and
CP55940 is a competitive antagonists of GPR55 [14]. Furthermore,
cannabinoids, including THC, anandamide, 2-AG, O1602, and
abnormal cannabidiol, were shown to have no effect on b-arrestin-
dependent ligand-mediated activation of GPR55, and CP55940
was shown to be a GPR55 antagonist/partial agonist [15]. These
cannabinoids also do not appear to activate extracellular signal-
regulated kinase (ERK) 1/2 via GPR55 [16]. However, it should be
mentioned that the majority of the abovementioned studies utilized
HEK293 cells that overexpress GPR55. Consequently, there may
be inconsistencies in these results, and therefore someof the findings
might be controversial [17]. Despite this, it has been demonstrated
that lysophosphatidylinositol (LPI) activates ERK1/2 and increases
[Ca
2+]i via GPR55 [16]. There is no evidence that LPI interacts
with the other cannabinoid receptors, particularly CB1 and CB2.
Since this study, more detailed signaling pathway and role of
GPR55 have been examined using LPI as a GPR55 agonist. For
example, LPI promotes RhoA-dependent Ca
2+ signaling and
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inhibits mouse osteoclast formation through the activation of Rho
and ERK1/2 [18]. However, the role of GPR55 and LPI in
neuronal cells remains unclear.
In the present study, we show that rat PC12 cells, a neuronal
model cell line, express endogenous GPR55. Thus, the objective of
the present study was to determine the effects of cannabinoids on
the signaling and physiological roles of GPR55 in PC12 cells.
Herein, we demonstrated that LPI, not cannabinoids, stimulates
GPR55 signaling and causes neurite retraction in PC12 cells
differentiated by nerve growth factor (NGF).
Materials and Methods
Materials
CP55940 and cannabidiol were purchased from Tocris
(Ellisville, MO). Anandamide was purchased from Biomol
Research Labs, Inc. (Plymouth Meeting, PA). 2-AG was purchased
from Cayman Chemical Company (Ann Arbor, MI). TRI
ReagentH, LPI, lysophosphatidic acid (LPA), UTP, CGS21680,
NGF, luciferin, Hoechst-33258 and anti-neurofilament light chain
antibody were purchased from Sigma-Aldrich (St. Louise, MI).
Y27632 was purchased from Calbiochem (San Diego, CA). Fura-2
was purchased from Dojindo (Kumamoto, Japan). Phalloidin-
Rhodamine was purchased from Molecular Probes (Eugene, OR).
Antibodies against phospho-ERK1/2, ERK1/2, glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) and horseradish peroxidase
(HRP)-conjugated rabbit IgG were from Cell Signaling. Anti-
GPR55 was from Enzo Life Sciences (Plymouth Meeting, PA).
Anti-RhoA antibody was from Santa Cruz (Santa Cruz, CA). Anti-
HA antibody was from Roche (Manheim, Germany). Enhanced
chemiluminescence (ECL) assay kit and HRP-conjugated anti-
mouse IgG were purchased from GE Healthcare (Buckingham-
shire, England). Alexa588-anti-rat IgG antibody and lipofectamine
2000 were purchased from Invitrogen (Grand Island, NY). pSRF/
Luciferase was purchased from Promega (Madison, WI). Rever-
TraAceH was purchased from Toyobo (Osaka, Japan). SYBRH
Premix Ex Taq
TM (Perfect Real Time) was purchased from
Takara (Otsu, Japan). siRNA for rat GPR55 was synthesized by B-
Bridge (Mountain View, CA), and the cocktail of three duplexes
was used, i.e. 1) sense 59-GGA GAC AGC UGG AAU ACA
UTT-39 and antisense 59-AUG UAU UCC AGC UGU CUC
CTT-39; 2) sense 59-CGA AAG AGA GCC UGC AUC ATT-39
and antisense 59-UGA UGC AGG CUC UCU UUC GTT-39;
and 3) sense 59-GCA GAG UGA AGC AGG GCA UTT-39 and
antisense 59-AUG CCC UGC UUC ACU CUG CTT-39. All
other chemicals were of reagent grade or the highest quality
available. Adenoviruses encoding p115-RGS and C3 were kindly
provided by Dr. Hitoshi Kurose (Kyushu University, Fukuoka,
Japan), DNA plasmid for HA-GPR55 was kindly provided by Dr.
Ken Mackie (Indiana University, Bloomington, IN), GloSensor
cAMP and endotoxin-free luciferin were kindly provided by
Promega, YM254890 was kindly provided by Astellas Pharma Inc.
(Tokyo, Japan), GST-Rhotekin was kindly provided by Dr. Naoki
Mochizuki (National Cerebral and Cardiovascular Center Re-
search Institute, Osaka, Japan), and Ga13Q266L was kindly
provided by Dr. Takeo Saneyoshi (Riken, Wako, Japan).
Cell culture
PC12 cells were obtained from the Japanese Cancer Research
Bank (Tokyo, Japan). The cells were grown in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% heat-inactivat-
ed fetal calf serum (Cell Culture Laboratory, Cleveland, OH), 5%
horse serum (Invitrogen), penicillin (50 units/ml), and streptomy-
cin (50 mg/ml) in an incubator containing 5% CO2 at 37uC.
SDS-polyacrylamide gel electrophoresis and Western
blotting
Electrophoresis was performed on 8–11% acrylamide gels.
Proteins were transferred electrically from the gel onto poly-
vinylidene difluoride membranes (Millipore, Bedford, MA) via the
semi-dry blotting method. Blots were blocked for 1 h with 5% low
fat milk in Tris-buffered saline containing 0.1% tween-20 (TBST)
at room temperature, and incubated with primary antibodies
overnight at 4uC. Blots were washed several times and incubated
with HRP-conjugated anti-rabbit or anti–mouse IgG antibody as a
secondary antibody in TBST containing 5% low fat milk at room
temperature for 2 h. After rinsing with TBST, blots were
developed using a chemiluminescence assay kit, and visualized
by exposing the chemiluminescence from the membrane to a
Hyper-film ECL.
Assay for neurite outgrowth
Cells were fixed with 4% paraformaldehyde, and the nuclei
were stained with Hoechst-33258. Photographs were taken with
CELAVIEW-RS100 (Olympus, Tokyo, Japan) [19]. The number
of nuclei and total length of neurites were calculated using
CELAVIEW software (Olympus, Tokyo, Japan), and then the
value of total neurite length divided by the number of nuclei was
expressed as a ratio of neurite length per cell (mm/cell). Data were
expressed as means 6 S.E.M. based on the values of the three
wells.
Luciferase assay
DNA plasmids were transfected into PC12 cells using the
transfection reagent Lipofectamine 2000. Briefly, cells were seeded
onto 24-well plates at 1610
5 (cells/well) and cultivated for a day.
DNA plasmids ([0.7–0.8 mg pSRF/luc and 0.2–0.3 mg b-galacto-
sidase] or [(0.45 mg pSRF/luc, 0.1 mg b-galactosidase and 0.45 mg
empty vector or G13Q266L)]) and transfection reagent (1 ml/tube)
were mixed gently in DMEM (10 ml/tube) and incubated for
20 min at room temperature. After addition of DMEM (40 ml/
tube), this entire mixture (50 ml/well) was transferred to cultured
media, which had been replaced with serum free-DMEM (200 ml).
Cells were incubated for 4–6 h at 37uC, and then media was
replaced with growth medium (500 ml) containing 10% fetal calf
serum and 5% horse serum. For the reporter gene assays, cells
were incubated with drugs at 37uC for 6–8 h after serum
starvation, and subjected to the luciferase assay. Cells were lysed
in lysis buffer (1% Triton X-100, 110 mM K2HPO4,1 5m M
KH2PO4, pH 7.8) (100 ml/well), and then, after centrifuging
lysates to remove cell debris, the supernatant (50 ml/tube) was
mixed with 300 ml of assay buffer (25 mM Gly-Gly, 15 mM
MgSO4, 5 mM ATP, 10 mM NaOH). The luciferase reaction was
started by adding 100 ml of luciferin solution (150 mM), and
luciferase activity was measured using a luminometer (GENE
LIGHT 55, Microtech Nition, Funabashi, Japan). As an internal
control, b-actin promoter-driven b-galactosidase activity was
measured in the lysates to normalize for transfection efficiency.
Adenoviral infection
PC12 cells were infected with adenoviruses encoding the RGS
domain of p115 Rho GEF and C3 toxin that inactivates G12/13
and RhoA, respectively [20,21]. The GFP gene was introduced to
monitor infection efficiency of these G-protein interfering mutants
or C3 toxin. The infection was carried out for two days at 100 moi.
Neurite Retraction by LPI via GPR55, G13 and RhoA
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day after infection, cells were incubated with NGF for a day and
stimulated with drugs for indicated times.
Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was isolated from PC12 cells or cerebellar granule
cells using the TRI ReagentH according to the manufacturer’s
protocol. Total RNA was reverse-transcribed using ReverTraAceH
and the oligo (dT) primer. Primer sequences used were as follows:
CB1 receptor sense primer 59-ATA AGA GGA TCG TCA CCA
GG-39 and antisense primer 59-AGT TCA GCA GGC AGA
GCA TA-39 (498 bp product); CB2 receptor sense primer 59-AAG
CCC TCG TAC CTG TTC AT-39 and antisense primer 59-AGG
CAC AGC ATG GAG CAG AA-39 (668 bp product); b-actin
sense primer 59-AGG GAA ATC GTG CGT GAC AT-39 and
antisense primer 59-TCC TGC TTG CTG ATC CAC AT-39
(467 bp product); GPR55 sense primer 59-CTC CCT CCC ATT
CAA GAT GA-39 and antisense primer 59-AAG ATC TCC AGG
GGG AAG AA-39 (342 bp product), and GAPDH sense primer
59-ACC ACA GTC CAT GCC ATC AC-39 and antisense primer
59-TCC ACC ACC CTG TTG CTG TA-39 (462 bp product).
PCR products were separated by electrophoresis through an
agarose gel and stained with ethidium bromide. An image of each
gel was digitally captured using FASIII (Toyobo). For quantifica-
tion of mRNA expression, real-time PCR was carried out in a
20 ml solution containing SYBER Premix Ex Taq (10 ml), RT
template (3 ml), water (6 ml) and primers (1 ml) using the DNA
engine Opticon System (MJ Research, Waltham, MA). The
amount of each PCR product was normalized to GAPDH, and
expressed as a percentage change relative to control siRNA
treatment.
Immunostaining
PC12 cells transfected with HA-GPR55 were fixed with 4%
paraformaldehyde and stained with anti-HA primary antibody
(1:100 dilution) and Alexa 588-conjugated anti-rat IgG secondary
antibody (1:500 dilution). Then, cells were observed with a
fluorescence microscope (Olympus IX70; Olympus, Tokyo,
Japan). Also, F-actin protein was stained with Phalloidin-
Rhodamine and observed with a confocal laser microscope
(DMRB/E, TCS-NT, Leica, Wetzlar, Germany).
Measurement of [Ca
2+]i
[Ca
2+]i levels were measured by monitoring the intensity of
fura-2 fluorescence. PC12 cells were washed with modified
Tyrode’s solution (137 mM NaCl, 2.7 mM KCl, 1.0 mM
MgCl2,0 . 1 8 m MC a C l 2, 10 mM HEPES, 5.6 mM glucose,
pH 7.4). Cells were then loaded with 1 mM fura-2/AM for
30 min at 37uC. Fluorescence intensity of fura-2 (excitation
wavelength at 340 nm and 380 nm, and emission wavelength at
510 nm) was measured using a spectrofluorometer (FP-6500,
J A S C O ,T o k y o ,J a p a n ) .
Measurements of cAMP levels
The GloSensor cAMP, a fusion gene of the cAMP-binding
domain of protein kinase A and firefly luciferase, was utilized to
measure cAMP levels in living cells. By binding to cAMP, the
conformation change results in increased luciferase activity
[22,23,24,25]. Briefly, cells were transfected with GloSensor
cAMP and b-galactosidase, and were incubated in Tyrode’s
solution (NaCl 137 mM, KCl 2.7 mM, MgCl2 1.0 mM, CaCl2
1.8 mM, NaH2PO4, 0.4 mM, Glucose 5.6 mM, Hepes 10 mM,
pH 7.4) containing D-luciferin (2 mM) (100 ml/well) for two hours
at room temperature. Then, cells were stimulated with 106drugs
(11 ml/well), and luminescence was measured with a luminometer
(GloMax, Promega, Madison, IL). As an internal control, b-actin
promoter-driven b-galactosidase activity was measured in lysates
to normalize for transfection efficiency.
Affinity assay for RhoA activation
The GST fusion protein of the Rho-binding domain of
Rhotekin was expressed in Escherichia coli following induction with
isopropyl-b-D-1-thio-galactopyranoside. Cells were lysed in ice-
cold lysis buffer (50 mM Tris-HCl (pH 8.0), 10% glycerol, 1%
nonidet P-40, 200 mM NaCl, 2.5 mM MgCl2, 1 mM phenyl-
methylsulfonyl fluoride, 1 mM leupeptin, 10 mg/ml soybean
trypsin inhibitor, 10 mM NaF, 0.1 mM aprotinin, and 1 mM
NaVO4). Protein concentrations were quantified using the
Bradford protein assay, and active RhoA was isolated, as described
previously [26]. Equivalent amounts of supernatant (1000 mg total
protein) was incubated with GST-Rhotekin (including the RhoA
binding domain) coupled to glutathione beads. Following an hour
of incubation at 4uC, beads were pelleted and rinsed three times
with ice-cold lysis buffer, and proteins were eluted from the beads
using 26Laemmli buffer.
Statistical analysis
Data are expressed as means 6 S.E.M. Significant differences
were determined using Student’s t-test, Dunnett’s or Tukey-
Kramer’s multiple comparison tests.
Results
Expression and intracellular localization of GPR55 in PC12
cells
Gene expression of cannabinoid-related receptors in PC12 cells
was determined by RT-PCR (Figure 1a). PC12 cells express
GPR55 mRNA, but not CB1 or CB2 mRNA, whereas rat
cerebellar granule neurons express both GPR55 and CB1 as we
recently reported [27]. PC12 cells also expressed GPR55 protein
as mouse 3T3-L1 adipocytes (Figure 1b). Intracellular localization
of GPR55 in PC12 cells was determined. HA-GPR55, where the
major band was about 37 kD, and the minor bands, which were
assumed to be glycosylated, were also visualized (Figure 1c). HA-
GPR55 was predominantly localized on plasma membranes in
undifferentiated PC12 cells (Figure 1d). However, in PC12 cells
that are differentiated by NGF, HA-GPR55 was abundantly
localized at the tip of neurites or on the ruffled border, in addition
to the plasma membrane, where neurite extension is regulated by
small G-proteins, including Rho, Rac1 and Cdc42 [28] (Figure 1d),
thus localization of GPR55 may suggests a potential role for this
protein in the regulation of neurites.
LPI causes Gq-mediated Ca
2+ increase and ERK1/2
phosphorylation and G13-mediated Rho activation
Although LPI is widely recognized as a GPR55 agonist [16,29],
the role of cannabinoids in GPR55 regulation remains unclear.
Given that most of these studies were conducted in HEK293 cells
that overexpress GPR55, we used PC12 cells that express
endogenous levels of GPR55 to assess the role of LPI and
cannabinoids in GPR55 activation by measuring [Ca
2+]i. LPI
induced a transient and concentration-dependent increase in
[Ca
2+]i that was completely blocked by the Gq inhibitor,
YM254890 (1 mM) [30] (Figures 2a and 2b). Additionally, the
potency of LPI (10 mM) was comparable to that of LPA and UTP.
However, cannabinoids, including 2-AG (10 mM), anandamide
Neurite Retraction by LPI via GPR55, G13 and RhoA
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affect [Ca
2+]i (Figure 2c). In addition to Ca
2+ release, ERK1/2
phosphorylation was investigated. LPI also induced ERK1/2
phosphorylation in a time and concentration-dependent manner
(Figures 3a and 3b). This ERK1/2 phosphorylation was also
completely blocked by YM254890, as observed in Figure 2a
(Figure 3c), suggesting that ERK1/2 phosphorylation may be
Gq-dependent.
RhoA was activity also examined through the pull-down assay
with the GST-Rhotekin Rho-binding domain as an index of
GPR55 interaction with LPI or cannabinoids. LPI (10 mM,
5 min) activated RhoA similarly to LPA (10 mM, 5 min)
(Figure 4a). RhoA-dependent serum-response element (SRE)
activation was also measured. Overexpression of the GTPase-
deficient Ga13 mutant (G13QL) resulted in significant SRE-
activation (Figure 4b). Additionally, LPI (10 mM, 6 h) increased
Figure 2. LPI, not cannabinoids, increase [Ca
2+]i levels in a Gq-dependent manner in PC12 cells. (a) PC12 cells loaded with fura-2 were
stimulated with LPI (10 mM) in the presence or absence of YM254890 (1 mM), and [Ca
2+]i levels were determined. (b) PC12 cells loaded with fura-2
were stimulated with LPI (1, 3 or 10 mM), LPA (10 mM) or UTP (100 mM) in the presence or absence of YM254890 (1 mM), and [Ca
2+]i levels were
determined. Data are represented by means 6 S.E.M. (n=3). YM254890 significantly blocked the increase in [Ca
2+]i by LPI (*P,0.05). (c) PC12 cells
loaded with fura-2 were stimulated with cannabinoids, including 2-arachidonoylglycerol (2-AG, 10 mM), anandamide (ANA, 10 mM), cannabidiol (CBD,
10 mM) and CP55940 (10 mM), and [Ca
2+]i levels were determined.
doi:10.1371/journal.pone.0024284.g002
Figure 1. PC12 cells express endogenous GPR55. (a) Total RNA was extracted from PC12 cells or rat cerebellar granule cells (CGC), and RT-PCR
was performed using a primer mixture corresponding to rat GPR55, CB1 or CB2. b-Actin was used as a control gene. (b) GPR55 protein expression in
PC12 cells and mouse 3T3-L1 adipocytes was determined by Western blotting. (c) PC12 cells were transfected with HA-GPR55, and protein expression
was determined by Western blotting. (c) PC12 cells were transfected with HA-GPR55 and incubated in the presence or absence of NGF (100 ng/ml)
for a day. Then, immunostaining with HA antibody was performed and localization of GPR55 was observed under a fluorescence microscope.
doi:10.1371/journal.pone.0024284.g001
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associated coiled-coil containing protein kinase (ROCK) inhib-
itor, Y27632 (10 mM) (Figure 4c). However, cannabinoids,
including CP55940 (10 mM), anandamide (10 mM), cannabidiol
(10 mM) and 2-AG (10 mM), did not increase SRE activity
(Figure 4d). These findings suggest that LPI, and not the
cannabinoids tested in the present study, can activate RhoA in
PC12 cells.
It has previously been demonstrated that GPR55 can couple
with Gq and G13, and as a result increase [Ca
2+]i and RhoA
activity [12,13]. However, the effects of GPR55 on cAMP levels
have not yet been demonstrated. Thus, in the present study, we
measured intracellular cAMP levels in living cells using a novel
fusion gene of the cAMP-binding domain of protein kinase A and
firefly luciferase [22,23,24,25]. This cAMP biosensor responds to
cAMP, and the luminescence levels increase based on intracellular
cAMP concentrations. An adenosine A2 receptor agonist,
CGS21680 (10 mM), increased intracellular cAMP levels. Howev-
er, LPI (10 mM) and the abovementioned cannabinoids (10 mM)
did not result in any cAMP production, despite GPR55
Figure 3. LPI induces phosphorylation of ERK1/2 in a time and concentration-dependent manner in PC12 cells. (a) PC12 cells were
stimulated with LPI (20 mM) for indicated periods, and then phosphorylation of ERK1/2 was determined by Western blotting. (b) PC12 cells were
stimulated with LPI (1–30 mM) for 5 min, and phosphorylation of ERK1/2 was examined by Western blotting. (c) PC12 cells were stimulated with LPI
(20 mM) for 5 min in the presence or absence of YM254890 (1 mM), and then phosphorylation of ERK1/2 was determined by Western blotting.
doi:10.1371/journal.pone.0024284.g003
Figure 4. LPI, not cannabinoids, activates RhoA in PC12 cells. (a) PC12 cells were stimulated with LPA (10 mM) or LPI (10 mM) for 5 min, and
then Rho-GTP was precipitated with GST-Rhotekin RBD, followed by Western blotting. (b) PC12 cells were co-transfected with pSRF/luc and
Ga13Q266L or an empty vector, and then luciferase activity was measured as an index of RhoA activation. Data represent means 6 S.E.M. (n=3).
Ga13Q266L significantly increased RhoA activity (*P,0.05). (c) PC12 cells were transfected with pSRF/luc, and then stimulated with LPI (10 mM) for 6 h
in the presence or absence of Y27632 (Y, 10 mM). Luciferase activity was measured as an index of RhoA activation. Data represent means 6 S.E.M.
(n=3). LPI significantly increased RhoA activity, which was reversed by Y27632 (*P,0.05). (d) PC12 cells were transfected with pSRF/luc, and then
stimulated with LPA (10 mM), LPI (10 mM), CP55940 (10 mM), anandamide (ANA, 10 mM), cannabidiol (CBD, 10 mM) or 2-arachidonoylglycerol (2-AG,
10 mM) for 6 h. Luciferase activity was measured as an index of RhoA activation. Data are represented by means 6 S.E.M. (n=3). Both LPA and LPI
significantly increased RhoA activity, whereas RhoA activity was not affected by any of the cannabinoids tested (*P,0.05).
doi:10.1371/journal.pone.0024284.g004
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interact with Gas.
LPI causes neurite retraction via GPR55, G13 and RhoA
Further, the effects of LPI on neurite elongation or retraction
were examined. In undifferentiated PC12 cells, LPI showed no
effect on neurite outgrowth (data not shown). However, in PC12
cells differentiated by NGF (100 ng/ml, 24 h), LPI (10 mM) and
LPA (3 mM), but not LPI (3 mM), caused rapid neurite retraction
(Figure 5). This dramatic change in neurite shape, induced by LPI,
was accompanied by redistribution of F-actin and loss of the
neurofilament light chain (Figure 6).
To determine the signaling pathway responsible for the LPI-
induced neurite retraction, cells differentiated by NGF were
pretreated with YM254890, and then stimulated with LPI. Neurite
retraction induced by LPI (10 mM) was not affected by YM254890
(1 mM) (Figure 7). Cells were infected with adenoviruses encoding
RGS domain of p115 RhoGEF (p115-RGS) or C3 toxin [20,21] to
determine the involvement of G13. p115-RGS binds to the bc
subunit-dissociated Ga12 or Ga13 and promotes GTP hydrolysis
by activating GTPase activity. C3 toxin causes ADP ribosylation
to Rho, one of the major effectors of Ga12 or Ga13. Cells were also
infected with adenoviruses encoding for GFP alone, and these cells
served as a control. LPI (10 mM) reduced neurite length, and this
effect was significantly reversed through inhibition of Ga13 or
RhoA function (Figure 8). Similarly, LPA-treated cells (3 mM) also
displayed neurite retraction via activation of these G-proteins, and
served as a positive control. These findings suggest that LPI-
induced neurite retraction is Gq-independent, and Ga13 and
RhoA-dependent.
Lastly, we attempted to determine whether the effects of LPI on
neurite retraction were via GPR55. It was previously demonstrat-
ed that cannabidiol is a GPR55 antagonist [12]. However, in our
study, cannabidiol did not affect LPI-induced increases in [Ca
2+]i
(data not shown). In addition to cannabidiol, it has been reported
that CP55940 is a competitive GPR55 antagonist [14] although
other studies demonstrated CP55940 showed a GPR55 agonistic
activity or no effect [12,16]. However, neither cannabidiol nor
CP55940 blocked LPI-induced neurite retraction in this study
(data not shown), thereby suggesting that cannabidiol and
CP55940 are not actually GPR55 antagonists. Thus, we used an
siRNA approach to investigate the involvement of GPR55.
GPR55 mRNA levels in cells treated with GPR55 siRNA were
decreased by 61% (Figure 9a), and LPI-induced neurite retraction
was significantly reversed in these GPR55 siRNA-treated cells
(Figure 9b) suggesting that LPI promotes neurite retraction via
GPR55. LPI-induced [Ca
2+]i elevation via Gq was also signifi-
cantly blocked by GPR55 knock down (Fig. 9c) in addition to G13
and RhoA-dependent neurite retraction.
Discussion
In the present study, we have demonstrated that LPI promotes
neurite retraction in PC12 cells through GPR55, G13 and Rho,
whereas cannabinoids, including anandamide, 2-AG, CP55940
and cannabidiol, do not interact with GPR55 in these cells
(Figure 10).
GPR55 was initially indentified as a novel target of cannabi-
noids, where it was demonstrated that endogenous, synthetic and
plant-derived cannabinoids, including THC, CP55940, ananda-
Figure 5. LPI induces neurite retraction in PC12 cells differentiated by NGF. PC12 cells were differentiated by NGF (100 ng/ml) for a day,
and then stimulated with LPI (3 or 10 mM) or LPA (3 mM) for indicated periods. Morphology of PC12 cells was observed and neurite length was
measured, as described in Materials and Methods. Scale bar=50 mm. Data are represented by means 6 S.E.M. (n=3). LPI (10 mM) or LPA (3 mM)
significantly caused neurite retraction (*P,0.05).
doi:10.1371/journal.pone.0024284.g005
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agonists, while cannabidiol is an antagonist determined by GTPcS
binding assay [12]. Since this initial discovery, many conflicting
observations have been made suggesting that cannabinoids do not
affect GPR55 signaling [17]. Nevertheless most of these studies
utilized HEK293 cells that overexpress GPR55, there results are
inconsistent and remain controversial with no clear explanation
for this discrepancy [17]. Therefore, in the present study, we
attempted to examine the agonistic effects of cannabinoids on
endogenous GPR55. We did not observe any agonistic effects of
cannabinoids on GPR55, as demonstrated by no changes in
[Ca
2+]i and Rho activity levels (Figures 2 and 4). In fact, we found
that only LPI activated GPR55 signaling in PC12 cells.
Unfortunately, the explanation for why cannabinoids do not
exhibit agonistic effects on GPR55 in PC12 cells remains
unknown.
GPR55 mRNA is expressed in the human brain determined by
northern blotting [11]. Recently, an intracellular phospholipase
A1, DDHD1, and cytosolic phospholipase A2, were identified as
LPI-synthesizing enzymes [31,32]. DDHD1 is widely distributed
and highly expressed in the brain [33], and therefore, considerable
levels of LPI may be synthesized in the brain. In fact, the rat brain
Figure 7. Gq is not involved in LPI-induced neurite retraction in PC12 cells differentiated by NGF. PC12 cells were differentiated by NGF
(100 ng/ml) for a day, and then stimulated with LPI (10 mM) for 30 min in the presence or absence of YM254890 (1 mM). Morphology of PC12 cells
was examined and neurite length was measured, as described in Materials and Methods. Scale bar=50 mm. Data are represented by means 6 S.E.M.
(n=3). LPI (10 mM) significantly induced neurite retraction (*P,0.05), however YM254890 did not reverse the effect.
doi:10.1371/journal.pone.0024284.g007
Figure 6. LPI induces neurite retraction accompanied by redistribution of b-actin and loss of neurofilament light chain in PC12 cells.
(a) PC12 cells were differentiated by NGF (100 ng/ml) for a day, and then stimulated with LPI (3 or 10 mM) or LPA (3 mM) for 15 min. Cells were fixed
and stained with rhodamine-phalloidin (5 U/ml), and observed with a confocal laser microscope. (b) PC12 cells were incubated in the presence or
absence of NGF (100 ng/ml) for a day, and then stimulated with LPI (10 mM) for 15 or 30 min. Contents of neurofilament light chain and GAPDH were
determined by Western blotting.
doi:10.1371/journal.pone.0024284.g006
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that endogenous GPR55, whose function is unclear, plays an
important role in the nervous system.
In differentiated PC12 cells, GPR55 is abundantly localized at
tips of neurites and on membranes of the ruffled border, in
addition to plasma membranes, where neurite extension is
Figure 8. G13 and RhoA are involved in LPI-induced neurite retraction in PC12 cells differentiated by NGF. PC12 cells were infected
with adenoviruses encoding p115-RGS or C3 toxin (100 moi) and differentiated by NGF (100 ng/ml) for a day. Cells were stimulated with LPI (10 mM)
or LPA (3 mM) for 30 min. Morphology of PC12 cells was examined and neurite length was measured, as described in Materials and Methods. Scale
bar=50 mm. Data are represented by means 6 S.E.M. (n=3). p115-RGS and C3 significantly reversed LPI (10 mM) or LPA (3 mM)-induced neurite
retraction (*P,0.05).
doi:10.1371/journal.pone.0024284.g008
Figure 9. GPR55 is involved in LPI-induced neurite retraction in PC12 cells differentiated by NGF. (a) PC12 cells were transfected with
GPR55 siRNA. Two days after transfection, total RNA was extracted and real-time RT-PCR was performed using primers corresponding to rat GPR55 or
GAPDH. (b) PC12 cells were transfected with GPR55 siRNA, and then cells were differentiated by NGF (100 ng/ml) for a day. Cells were stimulated with
LPI (5 or 10 mM) for 30 min. Morphology of PC12 cells was examined and neurite length was measured, as described in Materials and Methods. Data
are represented by means 6 S.E.M. (n=3). GPR55 siRNA significantly reversed LPI (5 or 10 mM)-induced neurite retraction (*P,0.05). (c) PC12 cells
were transfected with GPR55 siRNA, and then cells loaded with fura-2 were stimulated with LPI (10 mM), and [Ca
2+]i levels were determined.
doi:10.1371/journal.pone.0024284.g009
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(Figure 1d), suggesting that GPR55 may be involved in the
regulation of neurites. Although GPR55 stimulation with LPI did
not promote neurite outgrowth, LPI did trigger dynamic neurite
retraction with a loss of neurofilament light chain and actin
rearrangement within 30 minutes (Figures 5 and 6). Furthermore,
the LPI-induced neurite retraction appeared to be Ga13 and Rho-
dependent, and Gaq-independent (Figures 7 and 8). With respect
to the roles of heterotrimeric and small G-proteins in neurite
retraction, it has been shown that GPCR agonists that activate
Ga12,G a13 or small G-protein, Rho, can cause similar neurite
retraction in primary cultured hippocampal neurons, PC12 cells or
N1E-115 neuroblastoma cells. For example, overexpression of
constitutively active mutants of Ga12,G a13 or Rho results in
growth cone collapse and axonal retraction in hippocampal
neurons. A similar effect occurs with thrombin and LPA, which
activate the Ga12/13-Rho signaling pathway [34]. Another study
demonstrated that LPA induces growth cone collapse, neurite
retraction and cell flattening in differentiated PC12 cells, whereas
C3 toxin-treated neurites are resistant to retraction by LPA [35].
Imaging analysis in N1E-115 neuroblastoma cells revealed that
RhoA activity in shaft leads to neurite retraction and that in
peripheral domain of growth cones contributes to stabilization of
growth cone [36]. These reports support our hypothesis that LPI
induces neurite retraction via the GPR55/Ga13/Rho signaling
pathway. In the present study, LPI also stimulated phosphoryla-
tion of ERK1/2 through Gq in PC12 cells (Figure 3). It is generally
believed that sustained activation of ERK1/2 is necessary and
sufficient for neurite outgrowth in PC12 cells, which is achieved
through the activation of transcription factors that enhance gene
expression for neural differentiation. In fact, pharmacological
inhibition of ERK1/2 (i.e. using U0126 and PD98059) suppresses
neurite outgrowth [19,26], whereas the constitutively active
mutant of MEK induces neurite outgrowth in PC12 cells [37].
In the present study, it was found that LPI-induced neurite
retraction occurred in conjunction with ERK1/2 phosphorylation.
Therefore, it is suggested that RhoA activity may be dominate the
effects of ERK1/2 signaling, and thus, cells cannot extend their
neurites while RhoA is activated. In fact, NGF promotes neurite
outgrowth in PC12 cells while ERK1/2 is activated and RhoA is
inhibited [38].
LPI is synthesized by phospholipase A-mediated removal of one
of the acyl moieties of phosphatidylinositol. A commercially
available LPI reagent, used in the present study, is prepared from
soybean phosphatidylinositol hydrolyzed by phospholipase A2.
The main fatty acid group is palmitic acid esterified at sn-1
position. Recently, it was shown that 2-arachidonoyl LPI (with
arachidonic acid at sn-2) is a more potent ligand for GPR55 than
other LPI molecules, and the most predominant fatty acyl moiety
is stearic acid (50.5%) followed by arachidonic acid (22.1%) in the
brain [29]. Therefore, 2-arachidonoyl LPI is a better candidate for
a physiological GPR55 ligand. Future studies that examine the
potency of various LPI molecules on GPR55 are necessary.
Phospholipase A1/2 is activated in inflammatory responses,
during which lysophospholipids, including LPI, are generated with
major inflammatory mediators such as arachidonic acids.
Therefore, it can be speculated that LPI may play an important
role in inflammatory neurodegenerative diseases such as Alzhei-
mer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis
and multiple sclerosis. Whereas certain cannabinoid-related
compounds have been suggested to have promising effects in such
diseases [9], LPI/GPR55 signaling may actually enhance the
symptoms of these diseases because of LPI-induced loss of neural
cell function. Furthermore, it has previously been shown that bee
venom-mediated stimulation of phospholipase A2 and generation
of LPI promote secretion of insulin from pancreatic islet cells,
however involvement of GPR55 in this process was not established
[39]. Despite this, these findings suggest that LPI/GPR55 regulate
insulin secretion, and that drugs that target GPR55 may be used in
the treatment of diabetes. Additionally, LPI stimulates catechol-
amine secretion in PC12 cells [40], although this study did not
examine the involvement of GPR55. Furthermore, these findings
are corroborated by our preliminary experiments, where we also
observed that LPI induced marginal catecholamine secretion
(Obara et al., unpublished observation). Since lysophospholipids
have detergent-like properties and affect the functions of ion
channels and receptors on plasma membranes, GPR55 involve-
ment requires careful examination.
In conclusion, we demonstrated that LPI/GPR55 signaling
results in neurite retraction via G13 and RhoA in PC12 cells, and
that cannabinoids did not exhibit a similar effect on GPR55
signaling as LPI. Development of GPR55-specific agonists or
antagonists may have a therapeutic potential in the treatment of
inflammatory neurodegenerative diseases. Furthermore, studies
using animal models, such as GPR55 knockout mice, to examine
the physiological role of GPR55 in vivo are essential.
Supporting Information
Figure S1 LPI and cannabinoids do not increase
intracellular cAMP levels in PC12 cells. PC12 cells were
co-transfected with a cAMP indicator (i.e. a fusion gene of cAMP-
binding domain of protein kinase A and firefly luciferase), as well
as HA-GPR55 or empty vector. Then, cells were stimulated with
LPI (10 mM), anandamide (ANA, 10 mM), 2-arachidonoylglycerol
(2-AG, 10 mM), CP55940 (10 mM) or CGS21680 (10 mM) for
15 min, and luciferase activity was measured as an index of
intracellular cAMP levels in living cells as described in Materials and
Methods. Data are represented by means 6 S.E.M. (n=3).
CGS21680 significantly increased cAMP levels, whereas cannabi-
noids and LPI did not.
(TIF)
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